Highlights Gufic Biosciences Limited

Equities

GUFICBIO

INE742B01025

Delayed Bombay S.E. Other stock markets 12:54:12 2024-05-16 am EDT			5-day change	1st Jan Change
320.8 ^INR	-0.17%		+1.79%	+1.85%

Apr. 25	Gufic Biosciences Limited Approves Reconstitution of Various Committees	CI
Apr. 04	Gufic Biosciences Forms New Wholly-Owned Arm in Dubai	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Gufic Biosciences Forms New Wholly-Owned Arm in Dubai	Apr. 03	MT
Gufic Biosciences Limited Incorporates Wholly Owned Subsidiary Company in Dubai	Apr. 03	CI
Gufic Biosciences Secures Patent in India	Mar. 14	MT
Gufic Biosciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 14	CI
Gufic Biosciences Gets New Patent in India	Jan. 31	MT
Gufic Biosciences Forms New Pharmaceutical Subsidiary	Nov. 19	MT
Gufic Biosciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 09	CI
Lumosa Therapeutics Co., Ltd. Approves the Exclusive Licensing Agreement with Gufic Biosciences for LT1001, A Long-Acting Analgesic Injection	Nov. 09	CI
Gufic Biosciences Limited Approves Final Dividend for the Financial Year Ended March 31, 2023	23-09-30	CI
Gufic Biosciences Limited Approves Incorporation of Wholly Owned Subsidiary in Dubai, UAE	23-09-27	CI
Ex-dividend day for final dividend	23-09-20	FA
Gufic Biosciences Granted Patent for its Invention	23-09-14	MT
Gufic Biosciences Gets Nod from Australian, Brazilian Regulators for Parecoxib Sodium Lyophilized Powder	23-09-11	MT
Gufic Biosciences Limited Receives Approval of TGA, Australia and the National Health Surveillance Agency, Brazil for Parecoxib 40Mg Injection	23-09-11	CI
Gufic Biosciences Limited Proposes Final Dividend for the Financial Year Ended March 31, 2023	23-09-06	CI
Motilal Oswal Financial to Acquire 3% Stake in Gufic Biosciences for INR1 Billion	23-09-01	MT
Gufic Biosciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-11	CI
Gufic Biosciences Limited Receives Approval from NMPA, China for Prilocaine API	23-06-16	CI
Gufic Biosciences Limited Receives Approval from the Drug Controller General of India for Both Dalbavancin Api and Formulation	23-05-30	CI
Gufic Biosciences Limited Recommends Dividend for the Financial Year Ended March 31, 2023	23-05-29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Gufic Biosciences Limited

Equities

GUFICBIO

INE742B01025

Highlights

Filters